Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Average Rating of “Hold” from Analysts

Keros Therapeutics, Inc. (NASDAQ:KROS) has been assigned a consensus recommendation of “Hold” from the ten analysts that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, four have issued a hold rating and five have given a buy rating to the company. The average 1 year target price among analysts that have updated their coverage on the stock in the last year is $21.8571.

A number of brokerages recently commented on KROS. Wells Fargo & Company lowered their target price on Keros Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. TD Cowen upgraded Keros Therapeutics to a “hold” rating in a report on Friday, December 19th. Zacks Research cut Keros Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Thursday, January 1st. Wall Street Zen cut Keros Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 7th. Finally, Weiss Ratings restated a “sell (d+)” rating on shares of Keros Therapeutics in a report on Monday, December 29th.

Keros Therapeutics Trading Down 1.1%

NASDAQ KROS opened at $11.87 on Tuesday. The stock has a market cap of $234.08 million, a PE ratio of 6.52 and a beta of 0.98. Keros Therapeutics has a twelve month low of $9.12 and a twelve month high of $22.55. The stock has a fifty day simple moving average of $14.09 and a 200-day simple moving average of $16.44.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, March 4th. The company reported ($0.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.37). The business had revenue of $0.39 million for the quarter, compared to analysts’ expectations of $3.66 million. Keros Therapeutics had a return on equity of 14.25% and a net margin of 35.65%.The business’s revenue for the quarter was down 87.2% compared to the same quarter last year. During the same quarter in the prior year, the company posted ($1.14) earnings per share. Research analysts predict that Keros Therapeutics will post -4.74 EPS for the current year.

Hedge Funds Weigh In On Keros Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Caitong International Asset Management Co. Ltd boosted its holdings in Keros Therapeutics by 254.6% during the 4th quarter. Caitong International Asset Management Co. Ltd now owns 1,624 shares of the company’s stock valued at $33,000 after acquiring an additional 1,166 shares during the period. Invesco Ltd. boosted its holdings in Keros Therapeutics by 16.6% during the 4th quarter. Invesco Ltd. now owns 87,428 shares of the company’s stock valued at $1,780,000 after acquiring an additional 12,449 shares during the period. Empowered Funds LLC purchased a new position in Keros Therapeutics during the 4th quarter valued at about $1,223,000. XTX Topco Ltd purchased a new position in Keros Therapeutics during the 4th quarter valued at about $212,000. Finally, VARCOV Co. purchased a new position in Keros Therapeutics during the 4th quarter valued at about $261,000. 71.56% of the stock is currently owned by hedge funds and other institutional investors.

About Keros Therapeutics

Keros Therapeutics, Inc (NASDAQ: KROS) is a clinical-stage biopharmaceutical company dedicated to discovering and developing novel therapies for disorders of erythropoiesis and iron regulation. The company’s research centers on modulating the transforming growth factor-beta (TGF-β) superfamily to rebalance hematopoiesis and improve red blood cell production. By targeting key signaling pathways involved in anemia, Keros aims to provide new treatment options for patients with myelodysplastic syndromes, beta-thalassemia and other chronic anemias with significant unmet need.

The company’s lead product candidate, KER-050, is an engineered activin receptor ligand trap designed to restore effective erythropoiesis and reduce transfusion dependence in patients with anemia associated with myelodysplastic syndromes and primary myelofibrosis.